Results 261 to 270 of about 113,281 (294)
Some of the next articles are maybe not open access.
Cardiovascular safety and DPP‐4 inhibitors
Practical Diabetes, 2013Abstract Following the rosiglitazone controversy there is a requirement from the licensing agencies that new antidiabetic drugs must be shown not to increase cardiovascular risk during phase 3 development. This includes studying patients with high cardiovascular risk, who were previously excluded from phase 3 studies.
David M Carty +2 more
openaire +1 more source
[Once-weekly DPP-4 inhibitor].
Nihon rinsho. Japanese journal of clinical medicine, 2016Trelagliptin is the first once-weekly dipeptidyl peptidase-4(DPP-4) inhibitor in the world. Trelagliptin inhibits DPP-4 activity with lower drug concentration compared with other once- (or twice-) daily DPP-4 inhibitors in in vitro study. More than 70 % of DPP-4 activity is inhibited even 1 week after administration of trelagliptin administration in ...
Norio, Harada, Nobuya, Inagaki
openaire +1 more source
[DPP-4 inhibitors in nephropatics].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologiaThe use of glucose-lowering drugs in advanced stage diabetic nephropathic patients should be done very carefully. Some drugs are contraindicated or not recommended. The same insulin needs a dose reduction to avoid dangerous hypoglycemia. For some years the use of inhibitors of the DDP-4 has been approved in T2DM patients with CKD III and IV stage ...
Annamaria, Bruzzese +4 more
openaire +1 more source
Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor
Mini-Reviews in Medicinal Chemistry, 2020Sanjay Sharma +2 more
exaly